Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Regulatory Review topic
No spam. Unsubscribe anytime.
DOJ and state regulators to review HPH–HMSA filings; committee seeks enforceable conditions
Summary
Committee members were told the Department of Justice and state agencies are reviewing confidential filings from HMSA and HPH; witnesses said filings include proprietary actuarial data and that regulators can impose conditions, but public access is limited while inquiries are open.
Legislators at the April 8 informational briefing pressed HMSA and Hawaii Pacific Health for details about the regulatory path for One Health Hawaii and when the public can expect to see filings.
Witnesses said the organizations filed required materials with the U.S. Department of Justice, which decided it has jurisdiction to review the vertical integration for potential antitrust concerns and has been conducting interviews and document requests. HPH and HMSA described a multi-step review: an initial DOJ inquiry (which can trigger a secondary inquiry and depositions), parallel state-level reviews by the attorney general and the state insurance commissioner, and a separate review by the state health planning body (SHIPDA/SHIP) for certificate-of-need or change-of-ownership determinations.
Because regulatory submissions contain proprietary claims, pricing and actuarial analyses, witnesses said those documents are not made public while the inquiries are open. They explained DOJ typically examines submitted actuarial work and asks whether projected savings (in this case, the organizations' counsel provided a third-party actuarial validation) could be achieved without the proposed structural change. If DOJ has unresolved concerns it can file suit in federal court to block the integration; if it closes its inquiry without litigation, state regulators can still impose conditions before permitting operational changes.
Committee members asked whether regulators would publish findings or conditions; witnesses said regulators may release orders or conditions but that the timing and content depend on the agencies' practices and any confidentiality protections tied to the submitted proprietary data. Legislators urged that the committee be briefed on relevant documents or redacted findings and asked the companies to meet with the committee to identify measurable metrics regulators could use to monitor access and patient-mix outcomes.
No regulatory clearance or definitive timeline was presented at the briefing. Witnesses described the DOJ review as open-ended: a secondary inquiry could extend the timeline by months, while some state-level permitting paths could move in parallel and take weeks to months depending on hearing requirements. Committee leaders said they expect to continue oversight and asked the companies to provide additional follow-up to the committee and to cooperate with requests for specific monitoring metrics.
